Deep learning can predict prognosis and endocrine therapy response in breast cancer patients from H&E staining based on estrogen receptor signaling activity

Author:

Ng Chun Wai1,Wong Kwong-Kwok1

Affiliation:

1. The University of Texas MD Anderson Cancer Center

Abstract

Abstract Estrogen receptor (ER) expression status has long been a main factor for endocrine therapy. Deep learning methods can predict ER expression status by hematoxylin-and-eosin (H&E) staining. Since ER signaling activity has been found to be prognostic and is related to endocrine therapy responsiveness, we determined whether deep learning methods and whole-slide H&E-stained images could be used to predict ER signaling activity to determine prognosis in patients with breast cancer. ER signaling activity was determined using the Hallmark Estrogen Response Early gene set from the Molecular Signature Database (MSigDB). The data were fed into ResNet50 with three additional fully connected layers to predict the ER signaling activity of the samples, with ER signaling activity higher than the quantile 0.5. The trained model predicted that ER+/HER2- breast cancer patients with higher ER signaling activity had longer disease-free survival (p = 0.00415) and disease-specific survival durations (p = 0.00887). In conclusion, a convolutional deep neural network can predict prognosis and endocrine therapy response in breast cancer patients based on ER signaling activity using whole-slide H&E-stained images of tumors.

Publisher

Research Square Platform LLC

Reference30 articles.

1. Systemic therapy for estrogen receptor-positive, her2-negative breast cancer;Burstein HJ;N. Engl. J. Med.,2020

2. The evolving use of serds in estrogen receptor-positive, her2-negative metastatic breast cancer;Jeselsohn RM;Clin. Adv. Hematol. Oncol.,2021

3. Clinical review on the management of hormone receptor-positive metastatic breast cancer;McAndrew NP;JCO Oncol. Pract.,2022

4. Breast cancer: Conventional diagnosis and treatment modalities and recent patents and technologies;Nounou MI;Breast Cancer (Auckl.),2015

5. Presentation of the molecular subtypes of breast cancer detected by immunohistochemistry in surgically treated patients;Kondov B;Open Access Maced. J. Med. Sci.,2018

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3